BIIB
USDBiogen Inc. Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$128.495
最高价
$129.510
最低价
$127.420
成交量
1.14M
公司基本面
市值
18.8B
所属行业
Drug Manufacturers - General
国家/地区
United States
交易统计
平均成交量
1.49M
交易所
NMS
货币
USD
52周价格范围
相关新闻
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA
Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target
Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.
Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target
Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.
